The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19

Binbin Xia, Zheng Li, Yali Li, Wenfang Sun, Yang Liu, Liushui Li, Jingyao Pang, Jing Chen, Jiaxin Li, Hua ChengFrontiers in Pharmacology 2023 · DOI

This review paper synthesizes decades of research on Cepharanthine (CEP), a naturally occurring compound that has been used clinically in Japan for over 70 years. While originally approved for conditions like leukopenia and alopecia, recent high-throughput screens have identified it as one of the most potent small-molecule inhibitors of SARS-CoV-2, offering a multi-modal attack on the virus that remains effective against mutating variants.

TL;DR

Cepharanthine (CEP) is a "70-year-old new drug" candidate that inhibits SARS-CoV-2 at multiple stages, including viral entry and replication. While its oral bioavailability is low, its natural tendency to accumulate in lung tissue and its high potency when delivered via inhalation make it a promising, safe, and accessible tool for treating COVID-19.

What Problem Does This Paper Address?

The rapid mutation of the SARS-CoV-2 spike protein has frequently rendered vaccines and monoclonal antibodies less effective, particularly against variants like Omicron. To build a more resilient therapeutic arsenal, researchers are looking for small-molecule drugs that target highly conserved viral proteins or essential host-cell processes.

The challenge is that drug discovery is slow. This paper evaluates the strategy of drug repurposing—specifically focusing on CEP. The authors aim to bridge the gap between CEP’s historical use and its modern potential by summarizing its antiviral mechanisms, quantitative detection methods, and pharmacokinetic (PK) profile.

Methods

As a comprehensive review, the paper analyzes data from various experimental approaches:

  • In Vitro Assays: Evaluating CEP’s half-maximal inhibitory concentration ($IC_{50}$) across different cell lines (Vero E6, Calu-3, A549) and viral variants.
  • Molecular Docking: Using computational models to predict how CEP binds to viral targets like the Nsp13 helicase and the $M^{pro}$ protease.
  • Pharmacokinetic Analysis: Comparing drug concentration-time curves across multiple species (rats, dogs, humans) and administration routes (oral, intravenous, and pulmonary).
  • Formulation Science: Reviewing novel delivery systems, such as Self-Emulsifying Drug Delivery Systems (SEDDS) and nebulized inhalation, designed to overcome CEP's poor oral absorption.

Datasets

The review synthesizes findings from:

  • Large-scale drug libraries (e.g., a screen of 2,406 clinically approved drugs where CEP emerged as a top performer).
  • Public protein and genome databases (PDB structures 6NUR and 7BW4 for docking).
  • Historical clinical data from 70+ years of CEP use in Japan.
  • Recent in vivo studies using hACE2 transgenic mice infected with SARS-CoV-2.

Key Insights and Ideas

  • Multi-Stage Inhibition: Unlike many antivirals that hit a single target, CEP is "promiscuous" in a good way. It blocks viral entry by interfering with Spike-ACE2 binding and inhibits replication by targeting the Nsp13 helicase and the Nsp12–Nsp8–Nsp7 polymerase complex.
  • Host-Factor Modulation: CEP hijacks host processes to the virus's detriment. It interferes with the NPC1 protein (involved in cholesterol trafficking), which disrupts the endocytic pathway the virus uses to enter cells.
  • The "Lung-First" Distribution: A critical "aha moment" in the PK data is that CEP naturally accumulates in the lungs at concentrations significantly higher than in the blood. Since the lungs are the primary battleground for COVID-19, this biodistribution is a major therapeutic advantage.
  • Synergy with Protease Inhibitors: CEP shows a synergistic effect when combined with drugs like Nelfinavir. This suggests that "cocktail" therapies could allow for lower doses of each drug, reducing potential side effects.

Key Results

  • Potency: In various studies, CEP demonstrated $IC_{50}$ values as low as 0.047 μM against certain SARS-CoV-2 variants. In one pangolin coronavirus model, it reduced viral content by 15,393 times compared to a control.
  • Bioavailability Hack: While oral bioavailability is poor (~5.65% in rats), pulmonary delivery (inhalation) achieved a bioavailability of 68.07%. This bypasses the "first-pass" metabolism of the liver and delivers the drug directly to the site of infection.
  • Safety: Because it has been used for decades at doses up to 100mg/day in humans, its safety profile is well-characterized, potentially allowing it to skip early-phase safety trials.

Limitations and Future Work

  • Clinical Gap: Despite the overwhelming in vitro and animal data, large-scale, double-blind human clinical trials specifically for COVID-19 are still limited or ongoing.
  • Formulation Challenges: Standard oral tablets are inefficient. Future work must focus on standardized aerosol/inhalation formulations to ensure consistent dosing in patients.
  • Sample Sizes: Many of the recent PK studies cited used small sample sizes (n=3 or 4), which may limit the statistical robustness of the absorption data.
  • PAINS Classification: The authors address whether CEP is a "Pan-Assay Interference Compound" (a chemical that gives false positives in screens). While CEP has some PAINS-like characteristics, it passed specific filters, suggesting its antiviral activity is genuine and not an experimental artifact.

Summary updated

Abstract

To effectively respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an increasing number of researchers are focusing on the antiviral activity of cepharanthine (CEP), which is a clinically approved drug being used for over 70 years. This review aims to provide a brief overview of CEP and summarize its recent findings in quantitative analysis, pharmacokinetics, therapeutic potential, and mechanism in antiviral and anti-SARS-CoV-2 activity. Given its remarkable capacity against SARS-CoV-2 infection <i>in vitro</i> and <i>in vivo</i>, with its primary target organ being the lungs, and its good pharmacokinetic profile; mature and stable manufacturing technique; and its advantages of safety, effectiveness, and accessibility, CEP has become a promising drug candidate for treating COVID-19 despite being an old drug.
BibTeX
@inproceedings{xia2023brief,
  author = {Binbin Xia and Zheng Li and Yali Li and Wenfang Sun and Yang Liu and Liushui Li and Jingyao Pang and Jing Chen and Jiaxin Li and Hua Cheng},
  title = {{The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1098972},
}
Figure